cases. All instances of self limiting liver injury not requiring admission would not have been detected. Severe liver disorders, on the other hand, may occur without early changes in standard liver function.10

Acute liver injury associated with use of non-steroidal anti-inflammatory drugs is considered to be the result of current rather than past exposure. Therefore we chose as the comparison group the same people who had taken non-steroidal anti-inflammatory drugs at a time when they were no longer taking the drugs.11 We compared the incidence rate of acute liver injury during the total person time when subjects were taking non-steroidal anti-inflammatory drugs with the incidence rate during the total person time when they were not. The use of the exposed population as its own comparison group contributes to a reduction in confounding. Risk characteristics that do not change with time will necessarily be the same for exposed and non-exposed patients. We must, however, consider the possibility of changes in the use of non-steroidal anti-inflammatory drugs when applying this kind of cross over study design. The decision to start or stop use may be influenced by the presence of prodromal symptoms of the acute liver injury. We could not directly assess the extent of bias related to the beginning of medication for early non-specific symptoms of liver injury not yet diagnosed. For the 12 current users, however, for whom information on the indication for use of non-steroidal anti-inflammatory drugs was recorded, osteoarthritis was the underlying clinical condition. We evaluated the pattern of stopping treatment. Only four out of the 18 patients in the group not currently taking non-steroidal anti-inflammatory drugs had filled a prescription for non-steroidal anti-inflammatory drugs two to six months before admission to hospital; four had filled one prescription seven to 12 months before admission; and the remaining 10 had not filled a prescription in the year before admission. Increasing the criterion for current use of non-steroidal anti-inflammatory drugs to up to 90 days after the prescription did not materially change the rate ratio estimate.

The effects if non-steroidal anti-inflammatory drugs can be seen most clearly in a population free of the “background noise” of hepatotoxicity induced by other drugs.12 In the subpopulation with no use of other hepatotoxic drugs the rate ratio estimate of the effect of non-steroidal anti-inflammatory drugs on acute liver injury was larger than in the overall population.

Some of the patients did not undergo tests to rule out infectious hepatitis. In addition, diagnostic tests for hepatitis C were not available during the study, and differential diagnosis for cholelithiasis was not always carefully considered. All these limitations must be considered when interpreting our results, and some cases may have been misclassified. Any misclassification, however, would be similar to the two groups and may therefore have resulted in some underestimation of the true relative risk. Given the low incidence of acute liver injury, the impact on the excess risk would have been small.

In summary, our results show that admissions to hospital for acute non-infectious liver injury are rare and that current use of non-steroidal anti-inflammatory drugs is associated with a twofold increase in the risk and an excess risk of five per 100 000 person years.

We thank Edith Malcolm and the staff of the pharmaco-epidemiology unit in Saskatchewan for their expert collaboration with the Saskatchewan health databases and the organisation of the medical record abstraction process and Drs David Henry (University of Newcastle), Hershel Jick (Boston University), and Bruno Stricker (Netherlands center for monitoring of adverse reactions to drugs), who read earlier versions of the manuscript.

This study was supported by a grant from CIBA-GEIGY AG, Basel. It is based in part on data provided by the Saskatchewan department of health. The interpretation and conclusions contained herein do not necessarily represent those of the government of Saskatchewan or the Saskatchewan department of health.


(Accepted 30 July 1992)

Generalised pustular psoriasis: response to topical calcipotriol

J Berth-Jones, J Bourke, K Bailey, R A C Graham-Brown, P E Hutchinson

Pustular psoriasis is a life threatening disease1 and usually requires treatment with systemic drugs which themselves carry significant risks. Calcipotriol, a vitamin D analogue, is an effective new topical treatment for psoriasis vulgaris.2 This is the first report of its use in pustular psoriasis.

Correspondence to: Dr J Berth-Jones.

BMJ 1992;305:868-9

Case reports

Three consecutive patients admitted with pustular psoriasis were treated with calcipotriol ointment 50 μg/g (Dovonex).

Case I—A 68 year old woman had been controlling her psoriasis using tar and betamethasone valerate ointment until three weeks before admission. Her skin then deteriorated until 45% of her body surface was affected by erythema and pustulation. Calcipotriol ointment was applied twice daily. Within 24 hours pustulation had completely resolved. She continued to improve and was discharged after three weeks to continue using the same treatment. In total, 300 g calcipotriol ointment was applied during the admission.


(Accepted 30 July 1992)
A PATIENT WHO CHANGED MY PRACTICE

Challenge of sarcoid heart disease

Paul Wood once lightly said that a physician should be a doctor who is prepared to diagnose a condition that he did not know existed—an exacting definition that would exclude many of us. I was humbled to learn that a patient I had seen was shown necropsy to have sarcoid heart disease, a condition that I was aware of, though I had never then diagnosed it, thought that I was quite prepared to do so, but had not even considered it in a case. In partial exoneration it was the fact that she had never been my patient, but I had been asked to see her because of her rhythm problems after a dilatation and curettage eight years before her death. She subsequently suffered from supraventricular tachycardia, left bundle branch block, partial heart block, transient complete heart block, and multifocal ventricular ectopic beats before reverting to supraventricular rhythm before her sudden death at the age of 59 in 1968.

She was the first of six cases of sarcoid heart disease that we published in 1972. I had always been dissatisfied with the dead end diagnosis of "cardiomyopathy" and these cases showed how the issue to be more precise in defining the diagnosis and also that sarcoid of the heart might be more common than we, or the literature, had previously thought.

This led me to canvass my colleagues for further cases. Many confessed that they had never even entertained the diagnosis. Soon we had a considerable number of cases on the files, always a disproportionate number from East Anglia. By 1974 we published 50 cases; by 1981, 197 cases; and by 1986 over 300 cases in the United Kingdom.

Before this study there was a single case report from the United Kingdom and before many years had passed our series probably outnumbered the entire reported world experience at that time. This intriguing disease with so many bizarre and puzzling manifestations fascinated me with its endless variations. We followed up all the cases and the resultant database was extensively consulted by colleagues in many parts of the world, and they added their own cases to the series. The many problems of diagnosis and management became better understood, though the mysteries of causation and occurrence, and indeed the aetiology of sarcoidosis itself, remain to be solved.

At least the problem has been brought out into the open, the need for recognition has been exposed, and several lives have been saved as a result. If only I had been more aware in 1960 we might have managed to save the first patient. An incidental spin off has been the number of international friendships that have resulted and the opportunities to lecture or give papers in 10 countries over the years.—HUGH A FLEMING, emeritus consultant cardiologist, Cambridge


Comment

Bed rest and emollients are undoubtedly beneficial in generalised pustular psoriasis. However, these seem unlikely to be entirely responsible for the improvement seen in our patients, since all three improved so promptly on treatment with calcipotriol. In case 2 it was very clear that the patient was growing increasingly weak and toxic after admission. Not only the pustulation but also her general condition improved rapidly with calcipotriol. Previous, less severe episodes in this patient had required far more aggressive treatment.

Irritant reactions are often seen with calcipotriol but did not present a problem in these cases. A more important potential hazard is hypercalcaemia. For chronic plaque psoriasis calcipotriol ointment has been used in large studies in quantities of up to 100 g weekly without any evident effect on calcium homeostasis. No data are available for other forms of the disease. The serum calcium concentration was therefore carefully monitored in each case and did not rise.

Calcipotriol may prove to be a new, effective, and relatively safe treatment for generalised pustular psoriasis. However, we emphasise the need for daily monitoring of the serum calcium value. This form of psoriasis remains a life threatening condition and will always require management in specialist dermatological units because of the accompanying severe metabolic complications and the risk of septicemia.

